Glioblastoma, GBM, Glioma
Conditions
Brief summary
This trial is an open-label, multicenter, Phase 0/2 trial that will enroll up to 50 participants with recurrent glioblastoma which are schedule for resection. In the lead-in cohort, a total of 10 participants will be enrolled into the proposed phase 0 clinical trial. Participants will be administered LY3214996 plus Abemaciclib prior to surgical resection of their tumor. If positive PK results are demonstrated in ≥50% of Phase 0 participants and at least 5 participants are enrolled into Phase 2, up to approximately 40 additional participants will be enrolled in the dose expansion cohort in order to achieve a total of 25 participants enrolled into Phase 2 (lead-in cohort + dose expansion).
Interventions
DRUGAbemaciclib
100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
DRUGLY3214996
400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
Sponsors
Nader Sanai
Barrow Neurological Institute
Ivy Brain Tumor Center
Eli Lilly and Company
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Prior resection of histologically diagnosed WHO Grade IV glioma defined as glioma participants who have progressed on or following standard (Stupp regimen) therapy, which included maximal surgical resection, temozolomide, and fractionated radiotherapy. 2. Recurrence must be confirmed by diagnostic biopsy with local pathology review or contrast-enhanced MRI. 3. Participants must have measurable disease preoperatively, defined as at least 1 contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm, as per RANO criteria. 4. Sufficient archival tissue available to confirm eligibility. 5. For gliomas, archival tissue must demonstrate: (a) RB positivity (≥20%) on immunohistochemistry (IHC); or, no RB mutations on next-generation sequencing (NGS), (b) Chromosomal loss of CDKN2A/B/C; or, CDK4/6 amplification on array CGH or NGS, (c) pERK positivity (\>30%) on IHC. 6. Ability to understand and the willingness to sign a written informed consent document (personally or by the legally authorized representative, if applicable). 7. Participant has voluntarily agreed to participate by giving written informed consent (personally or via legally authorized representative(s), and assent if applicable). Written informed consent for the protocol must be obtained prior to any screening procedures. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness. 8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other procedures. 9. Age ≥18 at time of consent 10. Have a performance status (PS) ≤2 on the Eastern Cooperative Oncology (Group (ECOG) scale (Oken et al. 1982) 11. Ability to swallow oral medications. 12. Participant has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by the local laboratory for eligibility): Adequate bone marrow function: * absolute neutrophil count ≥1,000/mcL * platelets (at time of surgery) ≥100,000/mcL * hemoglobin ≥8.0 g/dL Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion. Adequate hepatic function: * total bilirubin ≤1.5 X ULN Participants with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted. * AST(SGOT) ≤3 X institutional ULN * ALT(SGPT) ≤3 X institutional ULN 13. Confirmed negative serum pregnancy test (β-hCG) before starting study treatment or participant or participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause. 14. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 months after the end of treatment administration. 15. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner and for an additional 6 months after the end of treatment administration. 16. Agreement to adhere to Lifestyle Considerations throughout study duration 17. Participants who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to Day 1. A washout period of at least 21 days is required between last chemotherapy dose and Day 1 (provided the patient did not receive radiotherapy). 18. Participants who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and Day 1.
Exclusion criteria
1. Current use of coumarin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed. 2. Pregnancy or lactation. 3. Known allergic reactions to components of the abemaciclib or LY3214996. 4. Active infection or fever \>38.5°C requiring systemic antibiotic, antifungal or antiviral therapy within 4 weeks of Day 1. 5. Known to have active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis. 6. Known active systemic bacterial infection (requiring intravenous \[IV\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \[for example, hepatitis B surface antigen positive\]. Screening is not required for enrollment. 7. Have history of central or branch retinal artery or venous occlusion with significant vision loss or other retinal diseases that cause current visual impairment or would likely cause visual impairment over the time period of the study. 8. Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \<30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea). 9. Prior therapy with any CDK4/6 inhibitor or any ERK1/2 inhibitor. Prior therapy is defined as a therapeutic dosing. 10. Treatment with another investigational drug or other intervention within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer. 11. Have a mean QT interval corrected for heart rate (QTc) of ≥470 milliseconds on screening electrocardiogram (ECG) as calculated using the Bazett's formula. 12. The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 2: Progression-free survival | up to 60 months | Phase 2: 6-month progression-free survival (PFS6) rate measured from time of surgery to date of recurrence |
| Phase 0: Pharmacokinetic analysis of tumor tissue | 8 hour | Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in enhancing and non-enhancing tumor tissue |
| Phase 0: Pharmacokinetic analysis of cerebrospinal fluid (CSF) | 8 hour | Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in CSF |
| Pharmacokinetic analysis of plasma | Day 6 at 0, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose | Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in plasma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse Events | up to 30 days after the last study dose | Number of Adverse Events |
| Deaths | up to 60 months | Deaths |
| Incidence of drug-related toxicity | up to 30 days after the last study dose | Drug-related toxicity |
| Incidence of clinical laboratory abnormalities per CTCAE | up to 30 days after the last study dose | Clinical laboratory abnormalities per CTCAE |
| Incidence of treatment-emergent adverse events | up to 30 days after the last study dose | Treatment-emergent adverse events |
| Phase 0: PD Analysis | Intraoperatively | Phase 0: percentage of pRSK+, pERK+, pRB+, pFOXM1, MIB-1+ and Cleaved Caspase 3+ cells from the surgical tissue will be quantified and compared to baseline archival tissue. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORNader Sanai, MD
Deputy Director of the Ivy Brain Tumor Center
Outcome results
None listed